Related references
Note: Only part of the references are listed.Real-world effectiveness of ribociclib in metastatic breast cancer patients: Does dose affect survival?
Cristina Fernandez-Cuerva et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2023)
CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis
C. Mueller et al.
BREAST CARE (2023)
PALBOSPAIN: OBSERVATIONAL ANALYSIS OF FIRST-LINE THERAPY WITH PALBOCICLIB IN PATIENTS WITH HR+/HER2-METASTATIC BREAST CANCER (MBC) IN REAL-LIFE CONDITIONS
Noelia Martinez-Janez et al.
CANCER RESEARCH (2023)
Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study
Massimo Cristofanilli et al.
CLINICAL CANCER RESEARCH (2022)
ESO-ESMO fifth international consensus guidelines for breast cancer in young women (BCY5)
S. Paluch-Shimon et al.
ANNALS OF ONCOLOGY (2022)
Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2.
Richard S. Finn et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
MONARCH 3: Interim overall survival (OS) results of abemaciclib plus a nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+, HER2-advanced breast cancer (ABC)
M. P. Goetz et al.
ANNALS OF ONCOLOGY (2022)
Pooled exploratory analysis of survival in patients (pts) with HR+/HER2-advanced breast cancer (ABC) and visceral metastases (mets) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA (ML) trials
D. A. Yardley et al.
ANNALS OF ONCOLOGY (2022)
Management ofAbemaciclib-AssociatedAdverse Events in Patients with Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Safety Analysis ofMONARCH2 andMONARCH3
Hope S. Rugo et al.
ONCOLOGIST (2021)
Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
C. Louwrens Braal et al.
DRUGS (2021)
How selective are clinical CDK4/6 inhibitors?
Denisa Hendrychova et al.
MEDICINAL RESEARCH REVIEWS (2021)
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2,-3 and-7 trials in hormone receptor-positive, HER2-negative advanced breast cancer
Howard A. Burris et al.
BRITISH JOURNAL OF CANCER (2021)
Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer
Mridula A. George et al.
FRONTIERS IN ONCOLOGY (2021)
Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program
Marion Bertho et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2 A Randomized Clinical Trial
George W. Sledge et al.
JAMA ONCOLOGY (2020)
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
Dennis J. Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
The Roles of Cyclin-Dependent Kinases in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer
Lei Ding et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
PARSIFAL: A randomized, multicenter, open-label, phase II trial to evaluate palbociclib in combination with fulvestrant or letrozole in endocrine-sensitive patients with estrogen receptor (ER)[+]/HER2[-] metastatic breast cancer.
Antonio Llombart-Cussac et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Quantifying CDK inhibitor selectivity in live cells
Carrow I. Wells et al.
NATURE COMMUNICATIONS (2020)
A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor-Positive Breast Cancer
Sara M. Tolaney et al.
CLINICAL CANCER RESEARCH (2020)
CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
Rossana Roncato et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
Stephen R. D. Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Optimizing care for younger women with hormone receptor-positive, HER2-negative metastatic breast cancer
Richard de Boer et al.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2020)
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
Veronique Dieras et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2-Advanced Breast Cancer
Veronique Dieras et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2019)
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer
S. -A. Im et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
Stephen Johnston et al.
NPJ BREAST CANCER (2019)
Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical Activity
Marc Hafner et al.
CELL CHEMICAL BIOLOGY (2019)
Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases
N. C. Turner et al.
ANNALS OF ONCOLOGY (2018)
Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy et al.
LANCET ONCOLOGY (2018)
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2-Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Palbociclib Combined with Fulvestrant in Premenopausal Women with Advanced Breast Cancer and Prior Progression on Endocrine Therapy: PALOMA-3 Results
Sibylle Loibl et al.
ONCOLOGIST (2017)
MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR+/HER2- Metastatic Breast Cancer
Maura N. Dickler et al.
CLINICAL CANCER RESEARCH (2017)
Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial
John F. R. Robertson et al.
LANCET (2016)
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli et al.
LANCET ONCOLOGY (2016)
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
G. N. Hortobagyi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
The changing role of ER in endocrine resistance
Agostina Nardone et al.
BREAST (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
Implications of Bone-Only Metastases in Breast Cancer: Favorable Preference with Excellent Outcomes of Hormone Receptor Positive Breast Cancer
Su Jin Lee et al.
CANCER RESEARCH AND TREATMENT (2011)
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro
Richard S. Finn et al.
BREAST CANCER RESEARCH (2009)
Share Paper
